 This is Jack Hildick-Smith with Stern Investor Relations, and welcome to Cara Therapeutics Second Quarter 2020 Financial Results and Update Conference Call. Before we begin, let me remind you that statements made on todays call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the expected timing of the data readouts from the companys ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones of the companys product candidates including the companys projected time line for the submission of its first NDA, the potential for the companys product candidates to be alternatives in the therapeutic areas investigated, and the companys expected cash reach. 